Belimumab Is Associated with Lower Risk of Progression to LN Compared with Standard of Care in Patients with SLE (ACR Convergence 2025) - Sep 15, 2025 - Abstract #2453; Pres time: Oct 28, 2025; 10:30 AM - 12:30 PM; Location: Hall F1; In Person; "Index was defined as the date of initiation of belimumab or SOC (immunosuppressant [IS, except for use in LN initial therapy], intravenous glucocorticoids [GCs], or oral GC escalation to ≥20 mg/day prednisone-equivalent) between Jan 1, 2017, and Mar 31, 2023...Initiation of LN induction therapy served as a proxy for incident LN and was defined as earliest use of: subcutaneous belimumab 400 mg once-weekly for four doses; voclosporin; cyclophosphamide (either monotherapy or combined with MMF or azathioprine); high-dose MMF... Belimumab use was associated with a lower risk of initiating LN induction therapy versus SOC among patients with SLE, suggesting a potential renal protective effect through which belimumab may prevent progression to LN.Funding: GSK"
Clinical • Infectious Disease • Inflammatory Arthritis • Nephrology • Renal Disease
|
|
Maral DerSarkissian1; Yan Chen1; Ariel Chao1; Shumin Rui1; Bronwyn Moore2; Karen Worley3; Daniel Moldaver4; Jeffrey J. Ellis3; Aarat M Patel5
|